Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
February 22 2019 - 8:00AM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced that Susan Molineaux,
Ph.D, the company’s founder, president and chief executive officer,
will participate in a fireside chat at the SVB Leerink Global
Healthcare Conference at 3:30 p.m. ET on Thursday, February 28,
2019 in New York City. The presentation will be webcast live and
available for replay for up to 30 days at www.calithera.com in the
Investor Relations section.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused
on fighting cancer and other life-threatening diseases by
discovering, developing, and commercializing novel small molecule
drugs that target tumor and immune cell metabolism. Calithera is
headquartered in South San Francisco, California. For more
information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the timing of
Calithera’s clinical trials, the clinical and commercial potential
of its product candidates, Calithera’s ability to fund its clinical
programs, and Calithera’s receipt of clinical data from its
clinical trials. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release. Such
product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations with
respect to any of the foregoing matters may have a negative effect
on Calithera's stock price. Additional information concerning
these and other risk factors affecting Calithera's business can be
found in Calithera's most recent Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission, and other
periodic filings with the Securities and Exchange Commission at
www.sec.gov. These forward-looking statements are not guarantees of
future performance and speak only as of the date hereof, and,
except as required by law, Calithera disclaims any obligation to
update these forward-looking statements to reflect future events or
circumstances.
SOURCE: Calithera Biosciences,
Incorporated
CONTACT:Jennifer
McNealeyir@Calithera.com650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024